Focus on Zhangjiang, and Huang Pharmaceutical's largest innovative pharmaceutical production base started

And Huang Pharma held the opening ceremony of the innovative pharmaceutical production base in Zhangjiang, Shanghai on December 8th, and Huang Pharma (NASDAQ/LSE: HCM) held the opening ceremony at the Zhangjiang Hi-Tech Park in Shanghai yesterday to start construction of the large-scale innovative pharmaceutical production base (the "Shanghai base").
Shanghai Economic and Information Commission, Science and Technology Commission and other professional management institutions, Pudong New Area, Shanghai Free Trade Zone, Zhangjiang Management Committee, Zhangjiang Group and other relevant leaders, as well as China Pharmaceutical Holdings, AstraZeneca, Lilly and other cooperative enterprise representatives attended the opening ceremony.
shanghai base will become the largest production facility of He Huang Pharmaceuticals.
and Huang Pharmaceuticals currently have GMP-certified preparation production facilities in Suzhou, responsible for clinical supply and commercial supply of Ayut ® capsules.
and Huang Medicine will invest additional resources to support the construction of the Shanghai base and gradually expand the production team at the Shanghai base, which will have a capacity of up to five times that of the existing Suzhou production base. "Today we are pleased to welcome another important milestone in the history of The Development of Huang Medicine in Zhangjiang, Shanghai," said Mr. Christian Hogg, chief executive officer of
and Huang Pharmaceuticals, at the opening ceremony of the Shanghai Innovative Pharmaceuticals production base.
our innovation journey began in Zhangjiang, where our research team discovered and developed world-class innovative therapies for the benefit of patients.
Our self-developed Ayut ® capsules are already available in China, and two other drug candidates, surufatinib and savolitinib, have submitted applications for new drugs in China, which are expected to be approved for release next year.
while china's market leadership is consolidated, and Huang Pharma is accelerating its globalization.
we plan to submit a new drug to the U.S. Food and Drug Administration (FDA) by the end of this year.
shanghai site will significantly increase the production capacity of Huang Medicine, bringing locally developed innovative therapies to more patients in China and around the world.
" Shanghai base covers an area of 28,700 square meters.
The entire construction will be divided into two phases, with a total construction area of nearly 55,000 square meters, the first phase is mainly for the production of small molecular compounds, after completion of the planned annual production capacity of up to 250 million tablets, 550 million capsules, will be used to support our global clinical and commercial supply.
of the base is expected to expand to the production of large molecular compounds.
and Huang Pharmaceuticals Shanghai Innovative Pharmaceuticals Production Base Effect Map about He Huang Pharmaceuticals and Huang Pharmaceuticals (NASDAQ/LSE: HCM) are innovative biopharmaceutical companies in the commercial phase that have been developing targeted drugs and immunotherapy for cancer and immunological diseases worldwide for the past 20 years.
, a total of nine cancer candidates are being developed globally and have an extensive commercial network in China's home market.
to learn more, please visit: .
。